Voxelotor Oral Tablet
ApprovedWithdrawn 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease
Trial Timeline
Aug 9, 2023 → Aug 23, 2023
NCT ID
NCT05228821About Voxelotor Oral Tablet
Voxelotor Oral Tablet is a approved stage product being developed by Pfizer for Sickle Cell Disease. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05228821. Target conditions include Sickle Cell Disease.
What happened to similar drugs?
3 of 20 similar drugs in Sickle Cell Disease were approved
Approved (3) Terminated (9) Active (8)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05228821 | Approved | Withdrawn |
| NCT05561140 | Phase 3 | Terminated |
Competing Products
20 competing products in Sickle Cell Disease